Severe Cholestatic Hepatitis Caused by Thiazolidinediones: Risks Associated with Substituting Rosiglitazone for Troglitazone
- 1 January 2002
- journal article
- case report
- Published by Springer Nature in Digestive Diseases and Sciences
- Vol. 47 (7) , 1632-1637
- https://doi.org/10.1023/a:1015895925374
Abstract
Troglitazone maleate (Rezulin) has been associated with severe hepatotoxicity, which led to its withdrawal from the U.S. market in March 2000. Rosiglitazone maleate (Avandia) is being marketed as a...Keywords
This publication has 16 references indexed in Scilit:
- Lessons from the glitazones: a story of drug developmentThe Lancet, 2001
- Severe Cholestatic Hepatitis From Troglitazone in a Patient With Nonalcoholic Steatohepatitis and Diabetes MellitusAmerican Journal of Gastroenterology, 2001
- Unraveling the mechanism of action of thiazolidinedionesJournal of Clinical Investigation, 2000
- Troglitazone-Associated Hepatotoxicity Treated Successfully with SteroidsAnnals of Internal Medicine, 2000
- Hepatocellular Injury in a Patient Receiving Rosiglitazone: A Case ReportAnnals of Internal Medicine, 2000
- Rosiglitazone and Hepatic FailureAnnals of Internal Medicine, 2000
- Hepatotoxicity due to troglitazone: report of two cases and review of adverse events reported to the United States Food and Drug AdministrationAmerican Journal of Gastroenterology, 2000
- Oxidation of Troglitazone to a Quinone-Type Metabolite Catalyzed by Cytochrome P-450 2C8 and P-450 3A4 in Human Liver MicrosomesDrug Metabolism and Disposition, 1999
- Severe Hepatotoxicity Associated with TroglitazoneAnnals of Internal Medicine, 1999
- Hepatic Dysfunction Associated with TroglitazoneNew England Journal of Medicine, 1998